After serum-free suspension adaption and characterization, BioVector acquires the host cell for CHOK1-GenS cell line development system without chemical modification. In together with the high-expression proprietary pGenHT 1.0-DGV vector, the yield titer can reach an average of 4.35g/L , up to 8.70g/L.

The CHOK1-GenS system has been used in 40+ CMC&CMO projects in which 11 has got IND approvals.

細胞系開發(fā)是生物藥研發(fā)重要一環(huán)，鏈接了藥物發(fā)現(xiàn)與臨床前開發(fā)，是臨床前 CMC 開發(fā)的限速步驟。BioVector細胞系開發(fā)使用自主宿主細胞、表達載體，開發(fā)周期短，具有優(yōu)質(zhì)的交付記錄和項目開發(fā)經(jīng)驗。

而BioVector保藏中心的 BioVector CHOK1-GenS 細胞系表達系統(tǒng)經(jīng)過無血清懸浮馴化和檢定后得到，未

經(jīng)過基因改造，可以對外商業(yè)化授權(quán)，搭配自主開發(fā)的 pGenHT 1.0-DGV BioVector載體，能夠保證出色的抗體量表達（平均 4.35g/L，最高 8.7g/L）。

Supplier來源:BioVector NTCC Inc.
TEL電話:+86-010-53513060
Website網(wǎng)址: http://www.biovector.net